Analysts Offer Predictions for REGENXBIO FY2029 Earnings

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Stock analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for REGENXBIO in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will post earnings per share of $0.46 for the year. The consensus estimate for REGENXBIO's current full-year earnings is ($4.87) per share.

A number of other analysts have also weighed in on RGNX. StockNews.com lowered REGENXBIO from a "hold" rating to a "sell" rating in a research note on Thursday. Raymond James reiterated an "outperform" rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Morgan Stanley restated an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday. Finally, Chardan Capital reissued a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, REGENXBIO presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.82.

REGENXBIO Trading Down 0.9 %

Shares of RGNX stock traded down $0.07 on Thursday, reaching $7.88. 548,305 shares of the company's stock were exchanged, compared to its average volume of 1,270,127. The company's fifty day simple moving average is $8.52 and its 200 day simple moving average is $10.42. REGENXBIO has a 52 week low of $6.56 and a 52 week high of $28.80. The stock has a market capitalization of $390.38 million, a PE ratio of -1.57 and a beta of 1.28.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 2,510 shares during the last quarter. FMR LLC grew its position in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,656 shares during the last quarter. nVerses Capital LLC grew its position in shares of REGENXBIO by 183.3% in the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock worth $36,000 after buying an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in REGENXBIO by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock valued at $100,000 after acquiring an additional 3,720 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in REGENXBIO during the third quarter valued at approximately $140,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.